泛亞微透(688386.SH):目前公司用於醫療行業的膜材已實現少量銷售
格隆匯10月26日丨有投資者在投資者互動平台向泛亞微透(688386.SH)提問,“根據公開信息-發行註冊環節反饋意見落實函的回覆,ePTFE膜廣泛應用於人造心臟瓣膜及人造血管等重要領域,公司目前人造血管及心臟瓣膜研發及推廣的進展情況如何?未來是否會是公司重要的業績增長點?”
公司表示,作為醫療材料,膨體聚四氟乙烯(ePTFE)具有優異的醫療性能,例如,它是無毒的,具有良好的組織相容性,並且不致癌, 抗生物老化,長期植入人體不受影響,柔軟,有彈性等。作為美國戈爾的追隨者,ePTFE膜在生物製藥、醫療等領域的應用也是公司積極拓展的應用領域,目前,公司用於醫療行業的膜材已實現少量銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.